Results 221 to 228 of about 48,812 (228)

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

Annals of Oncology, 2013
H I Scher, T M Beer, O Hamid
exaly  

Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)

Annals of Oncology, 2013
John B A G Haanen, Paul Lorigan
exaly  

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

Annals of the New York Academy of Sciences, 2013
James P. Allison, Caroline Robert, Steven J O'Day   +2 more
exaly  

Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival

Annals of Oncology, 2013
Julie Delyon, Emilie Lanoy, Caroline Robert   +2 more
exaly  

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

Cancer, 2013
F Stephen Hódi, Reinhard Dummer, Jeffrey S Weber   +2 more
exaly  

Ipilimumab

Reactions Weekly, 2020
openaire   +1 more source

Data support longer recurrence-free survival with nivolumab than with ipilimumab for stage III or IV melanoma

Ca-A Cancer Journal for Clinicians
exaly  

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040☆

Annals of Oncology
Jaclyn Neely, Bassel F El-Rayes, Anthony B El-Khoueiry   +2 more
exaly